Imminence of New Gonorrhea Therapeutic Drugs is Evident as the Bacteria Grow ‘Super Resistant’ to Antibiotics: FactMR
According to a new study of FactMR, the gonorrhea therapeutics market will reach ~US$ 970 Mn in 2019, and estimated to register a 4% Y-o-Y over 2018. The gonorrhea therapeutics industry will remain influenced by increased attention on new developments in novel therapeutic compounds or antimicrobials for improving the success potential of future treatment. There has been a significant rise in the prevalence of gonorrhea that is resistant to components of dual antibiotic therapy – ceftriaxone and azithromycin, which is the only recommended treatment for gonorrhea. In addition, resistance to several other antibiotics apart from dual antibiotic therapy resulted in ‘super gonorrhea’, which has become a buzzword in the gonorrhea therapeutics market . With a slew of promising new antibiotics on the horizon, alongside surveillance, education and preventative measures to stymie prevalence of super-resistant gonorrhea, prospects seem bullish for the gonorrhea therapeutics market. Request S...